Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Growth factor based therapies and intestinal disease: Is glucagon-like peptide-2 the new way forward?
Author: Yazbek, R.
Howarth, G.
Abbott, C.
Citation: Cytokine and Growth Factor Reviews, 2009; 20(2):175-184
Publisher: Elsevier Sci Ltd
Issue Date: 2009
ISSN: 1359-6101
Statement of
Roger Yazbeck, Gordon S. Howarth and Catherine A. Abbott
Abstract: Inflammatory bowel disease (IBD) is a chronic, debilitating disease associated with severe damage to the intestinal mucosa. Glucagon-like peptide-2 (GLP-2) is a potent and specific gastrointestinal growth factor that is demonstrating therapeutic potential for the prevention or treatment of an expanding number of intestinal diseases, including short bowel syndrome (SBS), small bowel enteritis and IBD. The biological activity of GLP-2 is limited due to proteolytic inactivation by the protease dipeptidyl peptidase (DP)IV. Inhibitors of DPIV activity may represent a novel strategy to prolong the growth promoting actions of GLP-2. This review outlines evidence for the clinical application of GLP-2, its degradation resistant analogue, Teduglutide, and novel DPIV inhibitors in efficacy studies utilizing pre-clinical models of intestinal damage, in particular IBD.
Keywords: Animals
Inflammatory Bowel Diseases
Intestinal Diseases
Short Bowel Syndrome
Glucagon-Like Peptide 2
Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl Peptidase 4
Description: Copyright © 2009 Published by Elsevier Ltd.
DOI: 10.1016/j.cytogfr.2009.02.008
Description (link):
Appears in Collections:Agriculture, Food and Wine publications
Aurora harvest 5

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.